MedTrace Logo

Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients

NCT01055145 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2012-11-27

No results posted yet for this study

Summary

Fluoroquinolone is a one of the most important drugs for treatment of multidrug-resistant TB (MDR-TB). Among them, levofloxacin and moxifloxacin has been used most widely. However, there is no study to directly compare the efficacy of levofloxacin and moxifloxacin among MDR-TB patients. The investigators will compare the efficacy of levofloxacin and moxifloxacin through a prospective multicenter randomized open label phase III trial.

Conditions

Interventions

DRUG

levofloxacin, moxifloxacin

Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jae-Joon Yim, MD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-07-31
Completion
2012-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01055145 on ClinicalTrials.gov